Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I-II Study of PTX-200 Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients With Metastatic and Locally Advanced Breast Cancer

NCT01697293 is registered in ClinicalTrials.gov with Prescient Therapeutics, Ltd. as lead sponsor.

NCT NCT01697293
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01697293 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I-II Study of PTX-200 Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients With Metastatic and Locally Advanced Breast Cancer
Lead sponsor
Prescient Therapeutics, Ltd.
Phase
Phase 1/2
Overall status
Terminated
Start date
January 31, 2012
Completion date
June 30, 2020
Enrollment
34 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast adenocarcinoma, estrogen receptor positive, her2/neu negative, recurrent breast carcinoma, stage iib breast cancer, stage iiia breast cancer, stage iiib breast cancer, stage iiic breast cancer, stage iv breast cancer